AlzChem Group (ACT) H2 2025 earnings summary

Executive summary

• Achieved consolidated sales of EUR 562.1 million in 2025, near the forecasted EUR 580 million, despite a challenging European chemical environment.

• Group EBITDA rose 11% year-over-year to EUR 116.5 million, with EBITDA margin reaching a record 20.7%, surpassing the long-term target.

• Net income increased 17% to EUR 64 million, supporting a proposed 17% dividend increase to EUR 2.10 per share.

• Major investment programs underway, including EUR 120 million creatine expansion and Nitroguanidine plant expansion.

• Free float in shares rose to 74%, boosting stock trading volumes.

Financial highlights

• Sales increased by EUR 8 million year-over-year, with major growth in the U.S. and Europe, mainly from specialty chemicals.

• EBITDA grew by EUR 11 million, outpacing sales growth due to higher-margin specialty segment.

• Net income rose 18% to EUR 64 million; EPS increased 18.3% to EUR 6.28.

• Equity increased by EUR 51 million, though the equity ratio slightly declined to 41.8% due to balance sheet expansion.

• Free cash flow remained positive at EUR 40.1 million despite high CapEx; operating cash flow rose to EUR 137 million.

Outlook and guidance

• 2026 sales expected to reach EUR 600 million (+7%), with EBITDA forecast at EUR 126 million (+8%).

• Growth to be driven organically, especially by volume increases in specialty chemicals, human nutrition, and defense.

• Major capacity expansions in creatine and defense to support growth from 2027, with anticipated double-digit percentage increases in sales and EBITDA.

• Assumes stable global economy, high electricity prices, and no major currency or tariff shocks.

• Maintenance shutdown of carbide furnace in H1 2026 to add EUR 15 million in costs, impacting EBITDA.